ESSA Pharma
400 Oyster Point Blvd.
Suite 520
South San Francisco
CA
94080
United States
153 articles about ESSA Pharma
-
ESSA Pharma to Present at the Piper Sandler 35th Annual Healthcare Conference
11/21/2023
ESSA Pharma Inc. today announced that the Company will be presenting at the Piper Sandler 35th Annual Healthcare Conference on Thursday, November 30, 2023, at 12:00 p.m. ET in New York.
-
ESSA Pharma to Present at the Jefferies London Healthcare Conference
11/8/2023
ESSA Pharma Inc. today announced that the Company will be presenting at the Jefferies Healthcare Conference on Wednesday, November 15, 2023, at 8:30 a.m. GMT/ 3:30 a.m. ET in London.
-
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat
10/26/2023
ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the presentation of updated dose escalation data from its Phase 1/2 study evaluating masofaniten (formerly EPI-7386) in combination with enzalutamide at the 30th Annual Prostate Cancer Foundation Scientific Retreat.
-
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the European Society of Medical Oncology 2023 Congress
10/21/2023
ESSA Pharma Inc. announced the presentation of updated dose escalation data from its Phase 1/2 study evaluating masofaniten in combination with enzalutamide at the European Society of Medical Oncology 2023 Congress, taking place October 20-24, 2023, in Madrid, Spain.
-
ESSA Pharma Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
9/18/2023
ESSA Pharma Inc today announced the initiation of the Phase 2 portion of its Phase 1/2 study evaluating its lead candidate, masofaniten (formerly known as EPI-7386), a first-in-class N-terminal domain androgen receptor inhibitor, in combination with Astellas and Pfizer's antiandrogen enzalutamide in patients with metastatic castration-resistant prostate cancer ("mCRPC") naïve to second-generation antiandrogens.
-
ESSA Pharma Insiders Establish Automatic Securities Disposition Plans
8/31/2023
ESSA Pharma Inc. announced that each of its President and CEO, David R Parkinson and its Executive VP & COO, Peter Virsik, have established ASDPs in accordance with applicable US and Canadian securities legislation, including U.S. SEC Rule 10b5-1 and the recommended practices set forth in the Canadian Securities Administrators' Staff Notice 55-317 and the Company's internal policies.
-
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2023
8/8/2023
ESSA Pharma Inc., a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, provided a corporate update and reported financial results for the fiscal third quarter ended June 30, 2023.
-
ESSA Pharma Appoints Lauren Merendino to its Board of Directors
6/6/2023
ESSA Pharma Inc. today announced the appointment of Lauren Merendino , M.B.A., to its Board of Directors.
-
ESSA Pharma to Present at 2023 Jefferies Healthcare Conference
6/1/2023
ESSA Pharma Inc. today announced that the Company will be presenting at the Jefferies Healthcare Conference on Thursday, June 8, 2023 at 8:00 a.m. Eastern Time in New York.
-
ESSA Pharma to Present at JMP Securities Life Sciences Conference
5/11/2023
ESSA Pharma Inc. today announced that the Company will be presenting at the JMP Securities Life Sciences Conference on Tuesday, May 16, 2023 at 10:00 a.m. Eastern Time in New York.
-
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2023
5/9/2023
ESSA Pharma Inc., a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, provided a corporate update and reported financial results for the fiscal second quarter ended March 31, 2023.
-
ESSA Pharma to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
4/18/2023
ESSA Pharma Inc. today announced that the Company will be presenting at the 2023 Bloom Burton & Co. Healthcare Conference.
-
ESSA Pharma to Present at the Oppenheimer 33rd Annual Healthcare Conference
3/8/2023
ESSA Pharma Inc. today announced that the Company will be presenting at the virtual Oppenheimer 33rd Annual Healthcare Conference on Wednesday, March 15, 2023, at 11:20 a.m. Eastern Time.
-
ESSA Pharma Announces Presentations at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU)
2/13/2023
ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX) today announced that further analyses of initial clinical data from two Phase 1 studies of EPI-7386 in patients with metastatic castration-resistant prostate cancer ("mCRPC") will be presented at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium.
-
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2022
2/7/2023
ESSA Pharma Inc. today provided a corporate update and reported financial results for the fiscal first quarter ended December 31, 2022.
-
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2022
12/13/2022
ESSA Pharma Inc. today provided a corporate update and reported financial results for the fiscal year ended September 30, 2022.
-
ESSA Pharma to Participate in Two Upcoming Investor Conferences
11/10/2022
ESSA Pharma Inc. today announced that the Company will be participating in two upcoming investor conferences.
-
ESSA confirmed that Janssen has stepped away from a prostate cancer collaboration due to “operational recruitment challenges.”
-
Updated Results from the Phase 1/2 Study of ESSA's Lead Candidate EPI-7386 in Combination with Enzalutamide Highlighted at the 29th Annual Prostate Cancer Foundation Scientific Retreat
10/26/2022
ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX) today announced the presentation of updated clinical data from the first two cohorts of the Phase 1/2 study of ESSA's lead candidate EPI-7386 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer ("mCRPC").
-
ESSA Pharma Appoints Philip Kantoff to its Board of Directors
9/13/2022
ESSA Pharma Inc. today announced the appointment of Philip Kantoff , M.D., to its Board of Directors.